Global Pharmaceutical R&D Outsourcing Market 2023-2029

March 2023 | 73 pages | ID: GFEDC538AF7CEN
Gen Consulting Company

Abstracts

Pharmaceutical R&D outsourcing is a strategy where a pharmaceutical company contracts the services of a third-party organisation to carry out some aspects of its research and development activities. This outsourcing strategy is used to reduce costs, improve efficiency, and increase the speed of drug development. Pharmaceutical R&D outsourcing can involve a wide range of activities, including clinical trial management, drug discovery, drug formulation, and regulatory affairs. Outsourcing to a specialised organisation can help a company to gain access to expertise and technology that it may not have in-house. The global pharmaceutical R&D outsourcing market size is projected to grow by USD 53.0 billion from 2023 to 2029, registering a CAGR of 8.6 percent, according to the latest market data.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical R&D outsourcing market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, stage of development, organization size, therapy area, and region. The global market for pharmaceutical R&D outsourcing can be segmented by product: biologics, small molecules. The small molecules segment held the largest revenue share in 2022. Pharmaceutical R&D outsourcing market is further segmented by stage of development: clinical, non-clinical. Among these, the clinical segment was accounted for the highest revenue generator in 2022. Based on organization size, the pharmaceutical R&D outsourcing market is segmented into: large enterprises, small and medium enterprises (SMEs). The SMEs segment captured the largest share of the market in 2022. On the basis of therapy area, the pharmaceutical R&D outsourcing market also can be divided into: cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, infectious diseases, musculoskeletal disorders, oncology, others. According to the research, the oncology segment had the largest share in the global pharmaceutical R&D outsourcing market. Pharmaceutical R&D outsourcing market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the largest revenue share in 2022.

Market Segmentation
By product: biologics, small molecules
By stage of development: clinical, non-clinical
By organization size: large enterprises, small and medium enterprises (SMEs)
By therapy area: cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, infectious diseases, musculoskeletal disorders, oncology, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global pharmaceutical R&D outsourcing market with some of the key players being Boehringer Ingelheim GmbH, Charles River Laboratories International, Inc., Hangzhou Tigermed Consulting Co., Ltd., ICON plc, IQVIA Holdings, Inc., Labcorp Drug Development Inc, Lonza Group AG, PAREXEL International Corporation, Pharmaron Inc., Samsung Biologics Co., Ltd., Syneos Health, Inc., Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global pharmaceutical R&D outsourcing market.
To classify and forecast the global pharmaceutical R&D outsourcing market based on product, stage of development, organization size, therapy area, region.
To identify drivers and challenges for the global pharmaceutical R&D outsourcing market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pharmaceutical R&D outsourcing market.
To identify and analyze the profile of leading players operating in the global pharmaceutical R&D outsourcing market.

Why Choose This Report
Gain a reliable outlook of the global pharmaceutical R&D outsourcing market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY PRODUCT

Biologics
Small molecules

PART 6. MARKET BREAKDOWN BY STAGE OF DEVELOPMENT

Clinical
Non-clinical

PART 7. MARKET BREAKDOWN BY ORGANIZATION SIZE

Large enterprises
Small and medium enterprises (SMEs)

PART 8. MARKET BREAKDOWN BY THERAPY AREA

Cardiovascular diseases
Central nervous system disorders
Gastrointestinal disorders
Infectious diseases
Musculoskeletal disorders
Oncology
Others

PART 9. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 10. KEY COMPANIES

Boehringer Ingelheim GmbH
Charles River Laboratories International, Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON plc
IQVIA Holdings, Inc.
Labcorp Drug Development Inc
Lonza Group AG
PAREXEL International Corporation
Pharmaron Inc.
Samsung Biologics Co., Ltd.
Syneos Health, Inc.
Thermo Fisher Scientific Inc.
WuXi AppTec Co., Ltd.

DISCLAIMER